Navelbine
information and resources from the National Cancer Institute
NCI Thesaurus | Navelbine
(Other name for: vinorelbine)NCI Thesaurus | Navelbine
(Other name for: vinorelbine)
vinorelbine
Navelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unreseactable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Navelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Navelbine is indicated in combination with cisplatin.
GlaxoSmithKline Nov 05 2002
vinorelbine
Single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC).
GlaxoSmithKline Dec 23 1994
|
|
|
|
news articles
Hana Biosciences to License Three Targeted Cancer Drug Candidates ... Mar 17, 2006
Genetic Engineering News, Vinorelbine (Navelbine(R); GlaxoSmithKline), a microtubule inhibitor, is approved for use as a single agent or in combination with cisplatin for the first ...
Hana Paying Up To $42M For Inex’s Cancer Drugs Mar 17, 2006
BioWorld Online (subscription), Vinorelbine, branded Navelbine by GlaxoSmithKline plc, of London, also is a microtubule inhibitor, approved for use as a single agent or in combination with ...
Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ... Mar 6, 2006
Cancer Consultants (press release), Researchers affiliated with the FinHer Study have reported that Taxotere® (docetaxel) is superior to Navelbine® (vinorelbine) when given in addition to 5-FU ...
Prostate cancer: awaiting innovation Dec 8, 2005
Pharmaceutical Business Review Novacea’s recent co-development with Pierre Fabre means that Novacea is likely to investigate the use of its drug DN-101 with oral Navelbine for HRPC. ...
ADVENTRX Announces Positive FDA Pre-IND Meeting Outcome Dec 7, 2005
Biotech Intelligence (press release), ANX-530 has demonstrated the ability to markedly reduce injection-site irritation in pre-clinical testing, compared to Navelbine(R), GlaxoSmithKline's approved ...
AstraZeneca's Casodex may get boost Dec 8, 2005
Science Daily (press release) Insight: Prostate Cancer -- A Prostrate Market Waiting for Innovations," also predicted that Novacea's drugs -- DN-101 and oral Navelbine -- and newer ...
Prostate Cancer: New choice for hormone refractory patients Dec 8, 2005
PharmaLive.com (press release), ...s recent co-development with Pierre Fabre means that Novacea is likely to investigate the use of its drug DN-101 with oral Navelbine (vinorelbine) for HRPC. ...
Gamma-linolenic acid inhibits action of Her-2/neu, responsible for ... Nov 20, 2005
Xagena.it, ...with GLA sensitizes breast cancer cells to some chemotherapeutic drugs, such as Paclitaxel ( Taxol ), Docetaxel ( Taxotere ) and Vinorelbine ( Navelbine ). ...
|
|
